Neuberger Berman Group
TVTX icon

Neuberger Berman Group’s Travere Therapeutics TVTX Stock Holding History

Neuberger Berman Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
214,910
+24,148
+13% +$1.07M 0.01% 838
2026
Q1 		$5.67M Sell
190,762
-27,265
-13% -$815K ﹤0.01% 957
2025
Q4 		$8.33M Buy
218,027
+6,360
+3% +$207K 0.01% 849
2025
Q3 		$5.06M Buy
+211,667
New +$3.98M ﹤0.01% 964
2018
Q3 		– Sell
-17,000
Closed -$463K – 1704
2018
Q2 		$463K Sell
17,000
-10,000
-37% -$266K ﹤0.01% 1409
2018
Q1 		$604K Buy
+27,000
New +$643K ﹤0.01% 1318

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's TVTX Position: Q2 2026 in Review

Neuberger Berman Group increased its Travere Therapeutics (TVTX) stake by 13% in Q2 2026, buying an estimated $1.07M and bringing the position to 214,910 shares worth $12.2M. The position accounts for 0.01% of the portfolio, ranked #838.

Neuberger Berman Group first reported a position in TVTX in Q1 2018 and has held it in 6 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Neuberger Berman Group held 214,910 shares of Travere Therapeutics worth $12.2M as of Q2 2026.
  • Neuberger Berman Group bought 24,148 Travere Therapeutics shares in Q2 2026, an estimated $1.07M.
  • Travere Therapeutics made up 0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #838 holding.
  • Neuberger Berman Group first reported a position in Travere Therapeutics in Q1 2018 and has held it in 6 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.